EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Evaluation of serum TWEAK levels and treatment response in psoriasis and psoriatic arthritis: a prospective comparative case–control study of adalimumab and methotrexate

Eisa M Hegazy, Eslam Abdelfattah Sadek, Shimaa Saber Ahmed

Clinical Rheumatology · 2026-05 · 45 (5) · 2721-2729

DOI: 10.1007/s10067-026-07981-8 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Rheumatology, online erschienen am 18.03.2026. Verfasst von Eisa M Hegazy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology, and Andrology, Faculty of Medicine, Qena University, Qena, Egypt. eisa_mohamed4152@med.svu.edu.eg. Hauptthemen laut MEDLINE: Adalimumab, Cytokine TWEAK, Methotrexate, Arthritis, Psoriatic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: South Valley University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Psoriasis vulgaris and psoriatic arthritis (PsA) are chronic immune-mediated diseases with systemic impact. Tumor necrosis factor (TNF)–related weak inducer of apoptosis (TWEAK) is a pro-inflammatory cytokine implicated in immune regulation and tissue remodeling, but its role in psoriatic disease remains incompletely understood.

Methods

This prospective case–control study included 100 subjects: 30 psoriasis patients receiving adalimumab, 30 PsA patients receiving methotrexate, and 40 healthy controls. Serum TWEAK was measured by ELISA at baseline and after 24 weeks. PASI and DAPSA scores were evaluated at both visits.

Results

Baseline TWEAK was higher in psoriasis (3.85 ± 0.62 ng/mL) and PsA patients (4.12 ± 0.71 ng/mL) than in controls (1.95 ± 0.54 ng/mL, p < 0.001). After 24 weeks, TWEAK decreased in both the adalimumab (2.21 ± 0.49 ng/mL) and methotrexate groups (2.67 ± 0.53 ng/mL, p < 0.001). Clinical improvement assessed by PASI and DAPSA paralleled this biochemical reduction, suggesting that TWEAK may serve as a biomarker of treatment response. TWEAK showed a stronger correlation with PASI after 24 weeks of treatment than with DAPSA.

Conclusion

Elevated TWEAK reflects psoriasis and PsA activity. Adalimumab and methotrexate reduce TWEAK alongside clinical improvement, supporting its potential as a biomarker for treatment monitoring. Key Points • Serum TWEAK levels were substantially elevated in psoriasis and psoriatic arthritis patients in comparison to controls. • TWEAK levels decreased following treatment with methotrexate and adalimumab. • Clinical improvement and disease activity scores were positively correlated with a decrease in TWEAK levels. • TWEAK may be a valuable biomarker for the monitoring of treatment response in psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdalimumabCytokine TWEAKMethotrexateArthritis, PsoriaticPsoriasisAntirheumatic AgentsHumansMaleFemaleProspective StudiesCase-Control StudiesAdultMiddle AgedTreatment OutcomeBiomarkers

Stichwörter der Autor:innen

AdalimumabDAPSAMethotrexatePASIPsoriatic arthritisTWEAK

Substanzen

AdalimumabCytokine TWEAKMethotrexateBiomarkersTNFSF12 protein, humanAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Venereology, and Andrology, Faculty of Medicine, Qena University, Qena, Egypt. eisa_mohamed4152@med.svu.edu.eg.
  • Department of Public Health and Community Medicine, Faculty of Medicine, Qena University, Qena, Egypt.
  • Rheumatology and Rehabilitation Department, Faculty of Medicine, Luxor University, Luxor, Egypt.

Förderung

  • South Valley University

Zitieren

APA

Hegazy, E. M., Sadek, E. A., & Ahmed, S. S. (2026). Evaluation of serum TWEAK levels and treatment response in psoriasis and psoriatic arthritis: a prospective comparative case–control study of adalimumab and methotrexate. Clinical Rheumatology, 45(5), 2721-2729. https://doi.org/10.1007/s10067-026-07981-8

Vancouver

Hegazy EM, Sadek EA, Ahmed SS. Evaluation of serum TWEAK levels and treatment response in psoriasis and psoriatic arthritis: a prospective comparative case–control study of adalimumab and methotrexate. Clinical Rheumatology. 2026;45(5):2721-2729. doi:10.1007/s10067-026-07981-8

BibTeX
@article{Hegazy2026,
  author = {Hegazy, Eisa M and Sadek, Eslam Abdelfattah and Ahmed, Shimaa Saber},
  title = {Evaluation of serum TWEAK levels and treatment response in psoriasis and psoriatic arthritis: a prospective comparative case–control study of adalimumab and methotrexate},
  journal = {Clinical Rheumatology},
  year = {2026},
  volume = {45},
  number = {5},
  pages = {2721--2729},
  doi = {10.1007/s10067-026-07981-8}
}
Kostenlos starten →